Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADR012
MIFTS: 47

Adrenal Gland Disease

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adrenal Gland Disease

About this section

MalaCards integrated aliases for Adrenal Gland Disease:

Name: Adrenal Gland Disease 12 15
Adrenal Gland Diseases 44 73
Abnormality of the Adrenal Glands 29
Adrenal Gland Disorders 43

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9553
ICD9CM 35 255 255.9
MeSH 44 D000307
NCIt 50 C26690
SNOMED-CT 68 30171000
UMLS 73 C0001621
Sources

Summaries for Adrenal Gland Disease

About this section
MedlinePlus : 43 The adrenal glands are small glands located on top of each kidney. They produce hormones that you can't live without, including sex hormones and cortisol. Cortisol helps you respond to stress and has many other important functions. With adrenal gland disorders, your glands make too much or not enough hormones. In Cushing's syndrome, there's too much cortisol, while with Addison's disease, there is too little. Some people are born unable to make enough cortisol. Causes of adrenal gland disorders include Genetic mutations Tumors including pheochromocytomas Infections A problem in another gland, such as the pituitary, which helps to regulate the adrenal gland Certain medicinesTreatment depends on which problem you have. Surgery or medicines can treat many adrenal gland disorders. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Adrenal Gland Disease, also known as adrenal gland diseases, is related to corticosteroid-binding globulin deficiency and adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete. An important gene associated with Adrenal Gland Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and cAMP signaling pathway. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, kidney and pituitary, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An endocrine system disease that is located in the adrenal gland.

Wikipedia : 76 Adrenal gland disorders (or diseases) are conditions that interfere with the normal functioning of the... more...

Sources

Related Diseases for Adrenal Gland Disease

About this section

Diseases related to Adrenal Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 corticosteroid-binding globulin deficiency 31.5 HSD11B2 NR3C1 POMC SERPINA6
2 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 11.0
3 waterhouse-friderichsen syndrome 11.0
4 ovarian serous adenofibroma 10.2 NR3C1 POMC
5 hypothalamic disease 10.2 CRH POMC
6 gangliocytoma 10.2 CRH POMC
7 inappropriate adh syndrome 10.2 POMC REN
8 bronchus adenoma 10.2 POMC SST
9 bronchial adenomas/carcinoids childhood 10.2 POMC SST
10 acidophil adenoma 10.2 POMC SST
11 arthrogryposis, distal, type 3 10.2 NR3C2 REN
12 hypoaldosteronism 10.2 CYP11B2 POMC REN
13 premenstrual tension 10.2 CRH POMC REN
14 allergic urticaria 10.2 CRH NR3C1
15 pituitary infarct 10.2 POMC SST
16 diabetes insipidus 10.2 CRH POMC REN
17 chiasmal syndrome 10.2 POMC SST
18 acth deficiency, isolated 10.2 CRH POMC
19 pseudohypoaldosteronism, type i, autosomal dominant 10.2 NR3C2 REN
20 postural hypotension 10.2 REN SST
21 acth-secreting pituitary adenoma 10.2 CRH NR3C1 POMC
22 familial hyperaldosteronism 10.2 CYP11B1 CYP11B2 KCNJ5
23 pseudohyperkalemia, familial, 2, due to red cell leak 10.2 CYP11B2 NR3C2 REN
24 gonadal disease 10.2 CRH NR0B1 POMC
25 mental depression 10.2 CRH NR3C1 POMC
26 persistent fetal circulation syndrome 10.2 CRH HSD11B2 POMC
27 chronic fatigue syndrome 10.2 CRH NR3C1 POMC
28 sheehan syndrome 10.2 CRH POMC
29 pituitary carcinoma 10.2 CRH POMC SST
30 ectopic cushing syndrome 10.2 CRH POMC SST
31 male reproductive organ benign neoplasm 10.2 POMC PRKAR1A
32 anuria 10.2 HSD11B2 NR3C2 REN
33 primary pigmented nodular adrenocortical disease 10.2 NR3C1 POMC PRKAR1A
34 pituitary gland disease 10.1 CRH POMC SST
35 glucocorticoid deficiency 1 10.1 MC2R POMC
36 pancreatic endocrine carcinoma 10.1 POMC SST
37 hypoadrenalism 10.1 CRH POMC
38 glucose metabolism disease 10.1 POMC REN SST
39 hormone producing pituitary cancer 10.1 PRKAR1A SST
40 acquired metabolic disease 10.1 POMC REN SST
41 pituitary adenoma, prolactin-secreting 10.1 POMC PRKAR1A SST
42 mood disorder 10.1 CRH NR3C1 POMC
43 familial hypertension 10.1 CYP11B2 HSD11B2 NR3C2 REN
44 acute adrenal insufficiency 10.1 CYP11A1 POMC REN
45 nelson syndrome 10.1 CRH NR3C1 POMC SST
46 apparent mineralocorticoid excess 10.1 HSD11B2 NR3C1 NR3C2 REN
47 pheochromocytoma 10.0 CRH POMC REN SST
48 familial glucocorticoid deficiency 10.0 MC2R NR0B1 POMC REN
49 adrenal rest tumor 10.0 CYP11B1 CYP11B2 MC2R POMC
50 hypokalemia 10.0 HSD11B2 NR3C1 NR3C2 POMC REN

Comorbidity relations with Adrenal Gland Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential

Graphical network of the top 20 diseases related to Adrenal Gland Disease:



Diseases related to Adrenal Gland Disease
Sources

Symptoms & Phenotypes for Adrenal Gland Disease

About this section

GenomeRNAi Phenotypes related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.32 ATP1A1 ATP1A4 CYP11B1 HSD11B2 KCNJ5 MC2R

MGI Mouse Phenotypes related to Adrenal Gland Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ATP1A1 CACNA1D CRH CYP11A1 CYP11B1 HSD11B2
2 homeostasis/metabolism MP:0005376 10.36 ARMC5 ATP1A1 ATP1A4 CACNA1D CRH CYP11A1
3 cardiovascular system MP:0005385 10.31 ATP1A1 CACNA1D CYP11A1 CYP11B1 CYP11B2 HSD11B2
4 growth/size/body region MP:0005378 10.28 ARMC5 ATP1A4 CACNA1D CRH CYP11A1 CYP11B1
5 endocrine/exocrine gland MP:0005379 10.2 ARMC5 CACNA1D CRH CYP11A1 CYP11B1 CYP11B2
6 cellular MP:0005384 10.18 ATP1A4 CACNA1D CRH CYP11A1 CYP11B1 HSD11B2
7 immune system MP:0005387 10.07 CRH CYP11A1 CYP11B2 MC2R NR3C1 POMC
8 mortality/aging MP:0010768 10.07 ARMC5 ATP1A1 CACNA1D CYP11A1 CYP11B1 HSD11B2
9 adipose tissue MP:0005375 10 CRH CYP11B2 MC2R NR3C1 POMC PRKAR1A
10 liver/biliary system MP:0005370 9.87 CRH CYP11A1 CYP11B2 NR3C1 POMC PRKAR1A
11 muscle MP:0005369 9.76 ATP1A1 CYP11A1 CYP11B1 HSD11B2 NR3C1 NR3C2
12 nervous system MP:0003631 9.65 CACNA1D CRH CYP11A1 CYP11B2 MC2R NR3C1
13 renal/urinary system MP:0005367 9.28 CRH CYP11B1 CYP11B2 HSD11B2 NR3C1 NR3C2
Sources

Drugs & Therapeutics for Adrenal Gland Disease

About this section

Drugs for Adrenal Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
3
Spironolactone Approved Phase 4,Phase 3,Not Applicable 52-01-7, 1952-01-7 5833
4
Eplerenone Approved Phase 4,Not Applicable 107724-20-9 443872 150310
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
7
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
9
Captopril Approved Phase 4 62571-86-2 44093
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
13
Cortisone acetate Approved, Investigational Phase 4,Phase 2,Not Applicable 1950-04-4, 50-04-4 5745
14
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 2 84371-65-3 55245
15
Cosyntropin Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 16960-16-0 16129617
16
Losartan Approved Phase 4 114798-26-4 3961
17
Angiotensin II Approved, Investigational Phase 4,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
18
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
20
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
23
Fludrocortisone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 127-31-1 31378
24
Cortisone Experimental Phase 4,Phase 2,Not Applicable 53-06-5 222786
25
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 diuretics Phase 4,Not Applicable
42 Diuretics, Potassium Sparing Phase 4,Not Applicable
43 Mineralocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
44 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Not Applicable
45 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Natriuretic Agents Phase 4,Not Applicable
48 Antiparkinson Agents Phase 4
49 Dopamine agonists Phase 4
50 Dopamine Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 381)
# Name Status NCT ID Phase Drugs
1 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
2 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
3 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
4 Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
5 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
6 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
7 Revival of Stem Cells in Addison's Study Completed NCT01371526 Phase 4 depot tetracosactide
8 Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Completed NCT00155064 Phase 4 captopril, Losartan (drug)
9 Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment Completed NCT00975078 Phase 4 prednisone
10 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
11 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
12 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
13 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
14 Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment Recruiting NCT03760835 Phase 4 Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone);Dual release hydrocortisone (plenadren)
15 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
16 Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism Enrolling by invitation NCT02282150 Phase 4 Hydrocortisone;Plenadren
17 Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers Not yet recruiting NCT03752190 Phase 4 Cosyntropin
18 A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) Not yet recruiting NCT03210545 Phase 4 Dexamethasone
19 Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency Terminated NCT01089075 Phase 4 Hydrocortisone;Placebo
20 Adrenal Insufficiency in Septic Shock Terminated NCT00842933 Phase 4 Corticosteroid;Corticosteroid
21 The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery Withdrawn NCT01045876 Phase 4 Dexamethasone
22 Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis Withdrawn NCT00368381 Phase 4 Hydrocortisone
23 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
24 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3 I-131 Iodocholesterol
25 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
26 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency Completed NCT00915343 Phase 2, Phase 3 hydrocortisone (modified release), oral tablet 20 and 5 mg;Hydrocortisone, oral tablet, 10 mg
27 Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency Completed NCT00575341 Phase 3 Dehydroepiandrosterone;placebo
28 SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Completed NCT01096654 Phase 3
29 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency Completed NCT00004313 Phase 3 dehydroepiandrosterone
30 Glucocorticoid Treatment in Addison's Disease Completed NCT01063569 Phase 2, Phase 3 Solu-Cortef (hydrocortisone);Cortef (hydrocortisone)
31 Treatment for Endogenous Cushing's Syndrome Completed NCT01838551 Phase 3 COR-003
32 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation Completed NCT00997594 Phase 2, Phase 3
33 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
34 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
35 The Role of Mineralocorticoid Receptors in Vascular Function Completed NCT00759525 Phase 2, Phase 3 Glycyrrhetic Acid;Placebo
36 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
37 MD1003-AMN MD1003 in Adrenomyeloneuropathy Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
38 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Completed NCT02716818 Phase 3 Chronocort®;standard glucocorticoid therapy
39 Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury Completed NCT01093261 Phase 3 Placebo;Hydrocortisone Fludrocortisone
40 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
41 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
42 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
43 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
44 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
45 A Study of the Efficacy and Safety of Relacorilant Recruiting NCT03697109 Phase 3 Relacorilant
46 Adrenal Artery Ablation for Primary Aldosteronism Recruiting NCT03653845 Phase 3 Sequenced antihypertensvie drugs with titrated dosage
47 Adrenal Artery Ablation Treats Primary Aldosteronism Recruiting NCT03398785 Phase 3
48 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. Recruiting NCT03277690 Phase 3 Levoketoconazole;Placebo
49 Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome Recruiting NCT02297945 Phase 3 metyrapone
50 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3

Search NIH Clinical Center for Adrenal Gland Disease

Cochrane evidence based reviews: adrenal gland diseases

Sources

Genetic Tests for Adrenal Gland Disease

About this section

Genetic tests related to Adrenal Gland Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Adrenal Glands 29
Sources

Anatomical Context for Adrenal Gland Disease

About this section

MalaCards organs/tissues related to Adrenal Gland Disease:

41
Adrenal Gland, Kidney, Pituitary, Cortex, Adrenal Cortex

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Gland Disease:

19
The Adrenal Gl
Sources

Publications for Adrenal Gland Disease

About this section

Articles related to Adrenal Gland Disease:

# Title Authors Year
1
Lateral Transperitoneal Adrenalectomy Versus Posterior Retroperitoneoscopic Adrenalectomy for Benign Adrenal Gland Disease: Randomized Controlled Trial at a Single Tertiary Medical Center. ( 29189215 )
2017
2
Serum inhibin concentration in dogs with adrenal gland disease and in healthy dogs. ( 23311716 )
2013
3
Adrenal gland disease in ferrets. ( 18165141 )
2008
4
Adrenal gland disease in ferrets. ( 9076915 )
1997
Sources

Variations for Adrenal Gland Disease

About this section
Sources

Expression for Adrenal Gland Disease

About this section
Search GEO for disease gene expression data for Adrenal Gland Disease.
Sources

Pathways for Adrenal Gland Disease

About this section

Pathways related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.29 ATP1A4 CACNA1D CRH KCNJ5 PRKAR1A
2
cAMP signaling pathway 37
Show member pathways
 12.1 ATP1A1 ATP1A4 CACNA1D MC2R
3
Aldosterone synthesis and secretion 37
Show member pathways
 12 ATP1A1 ATP1A4 CACNA1D CYP11A1 CYP11B1 CYP11B2
4
Cushing syndrome 37
Show member pathways
 11.91 ARMC5 CACNA1D CRH CYP11A1 CYP11B1 MC2R
5
Hepatic ABC Transporters 64
Show member pathways
 11.84 ATP1A1 ATP1A4 CACNA1D
6
Diseases of metabolism 66
Show member pathways
 11.7 CYP11A1 MC2R POMC
7
Nuclear Receptor transcription pathway 66
Show member pathways
 11.68 NR0B1 NR3C1 NR3C2
8
Corticotropin-releasing hormone signaling pathway 1
11.64 CRH CYP11A1 CYP11B1 POMC
9
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 61
Show member pathways
 11.62 CYP11B2 NR3C2 REN
10
Cardiac muscle contraction 37
11.59 ATP1A1 ATP1A4 CACNA1D
11
Metabolism of steroid hormones 66
Show member pathways
 11.5 CYP11A1 CYP11B1 CYP11B2 HSD11B2 POMC
12
Steroid hormone biosynthesis 37
Show member pathways
 11.44 CYP11A1 CYP11B1 CYP11B2 HSD11B2
13
Antiarrhythmic Pathway, Pharmacodynamics 61
11.38 ATP1A1 CACNA1D KCNJ5
14
Carbohydrate digestion and absorption 37
11.25 ATP1A1 ATP1A4 CACNA1D
15
Aldosterone-regulated sodium reabsorption 37
11.13 ATP1A1 ATP1A4 HSD11B2 NR3C2
16
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.9 CYP11B1 CYP11B2
17
Glucocorticoid Pathway (Peripheral Tissue), Pharmacodynamics 61
10.51 NR3C1 SERPINA6
18
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.32 CRH POMC
Sources

GO Terms for Adrenal Gland Disease

About this section

Cellular components related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase complex GO:0005890 8.62 ATP1A1 ATP1A4

Biological processes related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 ATP1A1 CRH HSD11B2 REN SST
2 steroid metabolic process GO:0008202 9.76 CRH CYP11A1 CYP11B1 CYP11B2
3 cholesterol metabolic process GO:0008203 9.75 CYP11A1 CYP11B1 CYP11B2
4 potassium ion import across plasma membrane GO:1990573 9.71 ATP1A1 ATP1A4 KCNJ5
5 potassium ion import GO:0010107 9.7 ATP1A1 ATP1A4 KCNJ5
6 adrenal gland development GO:0030325 9.63 CRH NR0B1
7 cellular sodium ion homeostasis GO:0006883 9.62 ATP1A1 ATP1A4
8 cardiac muscle cell action potential involved in contraction GO:0086002 9.62 ATP1A1 CACNA1D
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.61 ATP1A1 ATP1A4
10 cellular potassium ion homeostasis GO:0030007 9.61 ATP1A1 ATP1A4
11 cellular response to steroid hormone stimulus GO:0071383 9.6 ATP1A1 NR3C1
12 hypothalamus development GO:0021854 9.59 CRH NR0B1
13 sodium ion export across plasma membrane GO:0036376 9.58 ATP1A1 ATP1A4
14 sterol metabolic process GO:0016125 9.58 CYP11A1 CYP11B1 CYP11B2
15 cellular response to potassium ion GO:0035865 9.57 CYP11B1 CYP11B2
16 glucocorticoid metabolic process GO:0008211 9.56 HSD11B2 SERPINA6
17 regulation of blood pressure GO:0008217 9.56 ATP1A1 CYP11B1 POMC REN
18 hormone-mediated apoptotic signaling pathway GO:0008628 9.55 CRH SST
19 response to immobilization stress GO:0035902 9.54 CRH NR0B1 REN
20 cellular response to peptide hormone stimulus GO:0071375 9.5 CYP11A1 CYP11B1 CYP11B2
21 aldosterone biosynthetic process GO:0032342 9.49 CYP11B1 CYP11B2
22 cortisol biosynthetic process GO:0034651 9.48 CYP11B1 CYP11B2
23 steroid biosynthetic process GO:0006694 9.46 CYP11A1 CYP11B1 CYP11B2 NR0B1
24 regulation of blood volume by renal aldosterone GO:0002017 9.43 CYP11B2 HSD11B2
25 C21-steroid hormone biosynthetic process GO:0006700 9.13 CYP11A1 CYP11B1 CYP11B2
26 glucocorticoid biosynthetic process GO:0006704 9.02 CRH CYP11A1 CYP11B1 CYP11B2 HSD11B2

Molecular functions related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.61 CRH POMC SST
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.54 CYP11A1 CYP11B1 CYP11B2
3 ankyrin binding GO:0030506 9.46 ATP1A1 CACNA1D
4 steroid hormone receptor activity GO:0003707 9.43 NR0B1 NR3C1 NR3C2
5 sodium:potassium-exchanging ATPase activity GO:0005391 9.4 ATP1A1 ATP1A4
6 steroid hormone binding GO:1990239 9.32 ATP1A1 NR3C1
7 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
8 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2
9 steroid binding GO:0005496 8.92 HSD11B2 NR3C1 NR3C2 SERPINA6
Sources

Sources for Adrenal Gland Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....